MARKET

PGEN

PGEN

Precigen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.94
-0.37
-5.86%
Closed 18:23 11/23 EST
OPEN
6.30
PREV CLOSE
6.31
HIGH
6.45
LOW
5.93
VOLUME
819.53K
TURNOVER
--
52 WEEK HIGH
7.28
52 WEEK LOW
1.260
MARKET CAP
1.10B
P/E (TTM)
-6.1174
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dosing underway for Precigen's early-stage cancer cell therapy programs
Precigen (PGEN) has dosed the first patients with PRGN-3005 UltraCAR-T cells in the intraperitoneal arm of the ongoing Phase 1 study for advanced ovarian cancer patients, and with PRGN-3006 UltraCAR-T cells in
Seekingalpha · 11/16 14:13
Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical implementation of its UltraPorator™ system, a device exclusive to Precigen for the scale-up of rapid and cost-effective decentralized manufacturing of UltraCAR-T® therapies. Precigen and its clinical partners have now successfully dosed the first patients with UltraCAR-T cells manufactured using the UltraPorator system. The patients were dosed with PRGN-3005 UltraCAR-T cells in the intraperitoneal (IP) arm of the ongoing Phase 1 study for advanced ovarian cancer patients conducted in collaboration with the University of Washington/Fred Hutchinson Cancer Research Center and with PRGN-3006 UltraCAR-T cells in the ongoing Phase 1/1b study for patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS) conducted in collaboration with the Moffitt Cancer Center. UltraCAR-T eliminates ex vivo expansion, which reduces manufacturing time to allow for rapid next day administration of UltraCAR-T cells following non-viral gene transfer.
PR Newswire · 11/16 13:05
Precigen EPS misses by $0.04, beats on revenue
Precigen (PGEN): Q3 GAAP EPS of -$0.18 misses by $0.04.Revenue of $23.58M (+28.9% Y/Y) beats by $5.88M."The Precigen team has made impressive progress this quarter in driving value across our
Seekingalpha · 11/09 13:15
Precigen Q3 EPS $(0.18) Misses $(0.14) Estimate, Sales $23.58M Beat $17.70M Estimate
Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 47.06 percent increase over losses of $(0.34) per share from the
Benzinga · 11/09 13:12
Miller Value Partners is Betting on Precigen (PGEN) Stock
Insider Monkey · 11/02 16:12
Precigen Strengthens Focus on Strategic Partnerships and Names Gaurav Vij Head of Business Development
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Gaurav Vij as the Company's head of business development. Mr. Vij will have responsibility for accelerating strategic business development activities across Precigen's platform and pipeline programs, including identifying and building new strategic partnerships to rapidly progress core assets. Mr. Vij will report to Precigen's President and CEO, Helen Sabzevari, PhD, and will join Precigen's leadership team. This position adds to the ongoing evolution of Precigen's leadership team and supports the Company's continued focus on healthcare and strategic partnering of our innovative preclinical and clinical portfolio.
PR Newswire · 10/20 12:30
PGEN, GME, APHA and FSLY among midday movers
Gainers: Staffing 360 Solutions (STAF) +86%.China HGS Real Estate (HGSH) +65%.Huttig Building Products (HBP) +39%.Dragon Victory International (LYL) +35%.SPI Energy (SPI) +30%.Organogenesis (ORGO) +20%.Armata Pharmaceuticals (ARMP) +20%.Cars.com (CARS) +18%.Precigen (PGEN) +17%.GameStop (GME) +16%.Losers: Kaixin Auto
Seekingalpha · 10/15 16:47
Organogenesis Holdings, Anavex Life Sciences leads healthcare gainers; Vertex Pharmaceuticals, Aphria among major losers
Gainers: Organogenesis Holdings (ORGO) +22%, Anavex Life Sciences (AVXL) +16%, Precigen (PGEN) +12%, Replimune Group (REPL) +11%, Armata Pharmaceuticals (ARMP) +11%.Losers: Vertex Pharmaceuticals (VRTX) -20%, Aphria (APHA) -16%, Cyclerion Therapeutics (CYCN) -13%, Liquidia Technologies (LQDA) -9%, Arvinas (ARVN) -7%.
Seekingalpha · 10/15 15:12
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PGEN. Analyze the recent business situations of Precigen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PGEN stock price target is 9.00 with a high estimate of 13.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 272
Institutional Holdings: 126.01M
% Owned: 67.94%
Shares Outstanding: 185.46M
TypeInstitutionsShares
Increased
35
4.91M
New
44
288.79K
Decreased
47
2.99M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Executive Director
Randal Kirk
President/Chief Executive Officer
Helen Sabzevari
Chief Financial Officer/Primary Contact
Rick Sterling
Senior Vice President
Jeffrey Perez
Executive Officer
Donald Lehr
Lead Director/Independent Director
Robert Shapiro
Independent Director
Cesar Alvarez
Independent Director
Steven Frank
Independent Director
Vinita Gupta
Independent Director
Fred Hassan
Independent Director
Jeffrey Kindler
Independent Director
Dean Mitchell
Independent Director
James Turley
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
06/08/2015
Dividend USD 0.162
06/09/2015
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PGEN
Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Precigen Inc stock information, including NASDAQ:PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.